drug · small molecule
savolitinib
Phase 2updated 3mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 9 investigational indications.
indications
indications
NSCLC
targets
Hepatocyte growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying savolitinib
- phase2A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
- phase2Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
- phase2Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
- phase3Savolitinib vs. Sunitinib in MET-driven PRCC.
- phase3Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- phase3Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
- phase1A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers
- phase3Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that